Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs
© Xiao et al; licensee BioMed Central Ltd. 2011
Received: 1 September 2011
Accepted: 1 November 2011
Published: 1 November 2011
Highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS) has caused large economic losses in swine industry in recent years. However, current antiviral strategy could not effectively prevent and control this disease. In this research, five artificial microRNAs (amiRNAs) respectively targeted towards ORF5 (amirGP5-243, -370) and ORF6 (amirM-82, -217,-263) were designed and incorporated into a miRNA-based vector that mimics the backbone of murine miR-155 and permits high expression of amiRNAs in a GFP fused form mediated by RNA Pol II promoter CMV.
It was found that amirGP5-370 could effectively inhibit H-PRRSV replication. The amirM-263-M-263, which was a dual pre-amiRNA expression cassette where two amirM-263s were chained, showed stronger virus inhibitory effects than single amirM-263. H-PRRSV replication was inhibited up to 120 hours in the MARC-145 cells which were stably transduced by recombinant lentiviruses (Lenti-amirGP5-370, -amirM-263-M-263). Additionally, efficacious dose of amirGP5-370 and amirM-263 expression did not trigger the innate interferon response.
Our study is the first attempt to suppress H-PRRSV replication in MARC-145 cells through vector-based and lentiviral mediated amiRNAs targeting GP5 or M proteins coding sequences of PRRSV, which indicated that artificial microRNAs and recombinant lentiviruses might be applied to be a new potent anti-PRRSV strategy.
KeywordsHighly pathogenic PRRSV RNAi artificial miRNA Lentivirus
Porcine reproductive and respiratory syndrome (PRRS) is one of the most significant viral diseases in swine and it threats global swine industries. It has been reported that approximately 560.32 million US dollars lost annually only in the US. The causative of PRRS is porcine reproductive and respiratory syndrome virus (PRRSV), which is an enveloped, single-stranded positive-sense RNA virus and a member of the order Nidovirales, family Arteriviridae. The PRRSV genome, approximately 15 kb in length, encodes nine partially overlapping open reading frames (ORFs). Among them, ORF5 and ORF6 respectively encodes two PRRSV major envelope structural proteins: a glycosylated major envelope protein GP5 encoded by ORF5 and an unglycosylated membrane M protein encoded by ORF6. Both of these proteins are important to PRRSV infection[5–9], for example, PRRSV M/GP5 complex acts as the ligand to interact macrophage-specific lectin sialoadhesin which is critical for viral infection. In recent years, highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS) caused by highly pathogenic porcine reproductive and respiratory syndrome virus (H-PRRSV) is endemic in China and has resulted in enormous economic losses in swine-producing areas of the world[11, 12]. However, current antiviral strategy could not effectively prevent and control H-PRRSV. Hence, it is imperative to develop a safe and effective antiviral strategy to combat H-PRRSV infection.
RNA interference (RNAi) is a conserved natural mechanism by which homologous small interference RNA (siRNA) duplexes induce potent and sequence-specific posttranscriptional inhibition of gene expression via degradation of complementary messenger RNA (mRNA)[13, 14]. Since PRRSV is a RNA virus, its RNA genome is not only the template for viral transcription but also for viral genome replication. Antiviral RNAi might be more potent to be applied to inhibit RNA viruses, such as PRRSV[15, 16]. On the other hand, due to PRRSV infection in pigs is time persistent, there is a need to use stable antiviral RNAi therapy to durably protect pigs to combat PRRSV infection. Lentiviral vectors allow expressing exogenous DNA to induce stable and long-term gene silence in dividing and non-dividing cells[18, 19]. RNAi against viral infection based on lentiviral delivery has been intensively investigated and evaluated for potential therapeutic applications in HIV-1, Hepatitis viruses (Hepatitis B, HBV and Hepatitis C, HCV), Human papilloma virus, Coxsackie virus, Encephalitogenic flaviviruses, Prion disease, etc (reviewed in ). Recently, artificial microRNAs (amiRNAs) have been shown to be more effective than conventional short hairpin RNA (shRNA) as an antiviral strategy[20–25].
In this research, two recombinant plasmids expressing amiRNAs, which are designed to be perfectly homologous to PRRSV GP5 and M proteins coding sequences respectively, were found to be capable of inhibiting H-PRRSV replication without inducing innate interferon response. Additionally, it was found that H-PRRSV replication could be effectively inhibited in MARC-145 cells up to 120 h at least by stably transduced with recombinant lentiviruses expressing verified amiRNAs.
AmiRNAs design and target sites selection using luciferase assay
Construction of plasmids and titering lentiviral stock
Six amiRNAs expressing plasmids (pcDNA™6.2-GW/EmGFP-amirGP5-243; -amirGP5-370; -amirM-82; -amirM-217; -amirM-263; -amirM-263-M-263), two luciferase report plasmids psiCHECK2-GP5 and psiCHECK2-M, and three recombinant lentiviral expression plasmids (pLenti6/V5-GW/EmGFP-amirGP5-370; -amirM-263-M-263; -negative amiRNA) were constructed. All the nucleotides sequences inserted into vectors were confirmed by sequencing. The titers of the three recombinant lentiviruses were 3.35 × 106 TU/ml (Lenti-amirGP5-370), 3.33 × 106 TU/ml (Lenti-amirM-263-M-263), 1.81 × 106 TU/ml (Lenti-negative amiRNA).
Inhibition of cytopathic effect (CPE) induced by H-PRRSV in MARC-145
AmiRNAs specifically silence PRRSV genes in H-PRRSV infected MARC-145 cells
Interferon response is not triggered by efficacious amiRNAs
Duration of inhibitory effects on H-PRRSV in MARC-145 cells that stably transduced with Lenti-amiRNAs
Vaccination is the principal means used to control and treat PRRSV infection. An array of PRRS vaccines have been developed, but these all could not provide sustainable disease control because they suffer both from the immune evasion strategies of the virus and the antigenic heterogeneity of field strains. Hence, it is imperative to develop a safe and effective antiviral strategy to combat PRRSV infection. RNAi is a process of gene silencing which can be induced by intracellular expression of short hairpin RNA (shRNA) or artificial microRNA (amiRNA) delived by vectors or viruses. Previous researches have been demonstrated that PRRSV replication could be inhibited by RNAi induced by recombinant plasmids or adenoviruses expressing shRNAs[29–33]. Chen et al. (2006) demonstrated that adenovirus-mediated FMDV-specific shRNA could significantly reduce the susceptibility of swine to FMDV infection. Carmona et al. (2006) demonstrated that anti-HBx shRNA could effectively inhibited HBV replication.
However, shRNAs are not the optimal substrate for RNAi process in that shRNAs will not be processed by Drosha that could create cleavage sites for further cleave by Dicer which is critical for efficient RNAi effect. Therefore, it is required many candidate shRNA sequences to identify the effective ones. On the other hand, shRNA expressing vectors always use Polymerase III promoters, which not only limits tissue-specific expression of shRNA but also has shown to have higher possibilities to induce cellular toxicities due to over expression of shRNA driven by Polymerase III promoters might interfere with endogenous microRNA biogenesis.
Recently, pre-artificial microRNAs (pre-amiRNA) driven by Polymerase II promoters that via naturally existing endogenous microRNA pathway to become mature amiRNA have shown to be more potent antiviral RNAi inducers but with less dangerous of toxicities compared to conventional shRNAs[20–25]. RNA polymerase II is tightly regulated and it can drive tissue-specific amiRNA expression. In addition, endogenous microRNA pathway saturation caused by overexpression of exogenous shRNAs will be avoided by utilizing RNA polymerase II driven amiRNA expression constructs[38–41]. However, this has not been applied in the anti-PRRSV RNAi strategy.
In this research, five amiRNAs (amirGP5-243, amirGP5-370, amirM-82, amirM-217 and amirM-263) targeting PRRSV GP5 or M proteins coding sequences were designed via online tool. Then recombinant plasmids expressing theses amiRNAs were constructed. In the duel luciferase signal assay experiment, we observed that all amiRNAs could inhibit Renilla luciferase signal at least 70% via cleavage their target sequences. Except for amirM-82, inhibitory effects of all the other amiRNAs were found to be in dose dependent (Figure 2C and 2D). Our results indicated that amiRNAs-mediated RNAi might be a potent method to induce gene silence.
To investigate whether amiRNAs could inhibit accumulation of viral mRNAs or proteins of target genes, we carried out CPE analysis, real-time PCR, IFA and Western blotting assays. Among five amiRNAs tested in this study, amirGP5-370 showed the highest inhibitory effect on H-PRRSV replication and ORF5 gene expression in MARC-145 cells infected with H-PRRSV (Figure 4). Other four amiRNAs that were verified to be able to cleave target gene in duel luciferase assays failed to effectively knock down target viral genes in MARC-145 cells with H-PRRSV infection. It may be because of limited transfection efficiency and rapid replication of H-PRRSV. Efficiency of transfection of plasmids into MARC-145 cells using Lipofectamine 2000 in this study, which are measured by GFP fluorescence intensity, is approximately more than 50% (data not shown). Although this transfection efficiency is slightly higher than previous study using MARC-145 cells, it is still low and will underestimate the inhibition effects due to viral replication in those MARC-145 cells that failed to be transfected with amiRNAs. This case became more obvious when cells infected with H-PRRSV that will induce highly pathogenic lesions in cells. To combat rapid replication of H-PRRSV, increased inhibitory effects on target sequence are needed.
Chaining amiRNAs in one expression construct is permitted for the plasmids we used in this research. It also has been shown that increased gene knock-down effects could be induced by repeating same amiRNA in one expression construct. Among the other four amiRNAs, which showed less effective inhibition on H-PRRSV replication, amirM-263 showed greatest inhibitory effects. In this case, we chained two amirM-263s to construct a duel pre-amiRNAs construct amirM-263-M-263. It was observed that amirM-263-M-263 showed much higher inhibitory effects on viral gene transcription compared to amirM-263, and could inhibit H-PRRSV replication in MARC-145 cells (Figure 5 and 6).
Plasmids or adenoviruses delivery strategy is limited by its transient nature, as a result, RNAi effects were reduced over time post-infected with PRRSV and PRRSV could replicate afterwards. Also, PRRSV might develop certain mechanism to escape RNAi effect, but it is difficult to investigate possible virus escape in the condition of transient antiviral RNAi. Moreover, it has been shown that PRRSV infection can persist in pigs after preliminary infection. Taken together, antiviral RNAi against PRRSV infection should be a relatively stable therapy that can durably protect pigs. Lentiviral vector is a powerful DNA delivery tool that allows expressing exogenous DNA to induce stable and long-term gene silence in dividing and non-dividing cells[18, 19]. To date, lentiviral mediated RNAi have been intensively investigated for combat viral infection (reviewed in), but has not been reported to be used as an anti-PRRSV strategy. In this research, one of our aims is to investigate whether lentiviral mediated antiviral RNAi could persistently inhibit H-PRRSV replication in MARC-145 cells. Three recombinant lentiviruses expressing amirGP5-370, amirM-263-M-263 and negative amiRNA, respectively, were produced in 293FT cells. The results showed that H-PRRSV replication would be suppressed in MARC-145 cells stably expressed amirGP5-370 or amirM-263-M-263 up to 120 hours post infection (Figure 8).
Small interfering RNA (siRNA) may induce type I interferon (IFN-I) activation, which will result in off-target effects of RNAi in mammalian cells. However, in our research, efficacious dose of amirGP5 and amirM-263-M-263 will not trigger interferon response (Figure 7).
We designed five artificial amiRNAs respectively targeting PRRSV GP5 (amirGP5-243, -370) or M (amirM-82, -217,-263) proteins coding sequences and constructed recombinant plasmids expressing theses amiRNA. The results showed that amirGP5-370 and amirM-263-M-263 could effectively suppress H-PRRSV replication without inducing innate interferon response. And H-PRRSV replication could be effectively inhibited in MARC-145 cells up to 120 h at least by stably transduced with recombinant lentiviruses expressing verified amiRNAs. To our knowledge, the study presented here is the first attempt to suppress H-PRRSV replication in MARC-145 cells through vector-based and lentiviral mediated amiRNAs targeting GP5 or M proteins coding sequences of PRRSV. The study indicated that artificial microRNAs and recombinant lentiviruses might be applied to be a new potent anti-PRRSV strategy.
Design of amiRNAs and construction of plasmids expressing amiRNAs
Five precursor miRNAs (pre-miRNA) sequences respectively targeting on PRRSV GP5 and M protein coding genes were designed through an internet application system (Invitrogen). Double-stranded oligonucleotide encoding pre-miRNA sequence were annealed and inserted into pcDNA™6.2-GW/EmGFP-miR expression vector (Invitrogen) containing cytomegalovirus (CMV) promoter and herpes simplex virus thymidine kinase polyadenylation signal. All recombinant plasmids have been sequenced to confirm the sequences inserted.
Cell cultures, transfection and virus infection
African green monkey kidney cell line MARC-145 were applied to grow PRRSV and to determine virus titers. Human embryo kidney cells (293FT) were applied to produce lentivirus. MARC-145 cells and 293FT cells were both cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-glutamine, 0.1 mM MEM Non-Essential Amino Acids, 1% penicillin/streptomycin, and 1 mM MEM Sodium Pyruvate. Cells were typsinized and seeded in 96-well, 12-well or 6-well plate nearly 24 hours before tansfection. For transfection, lipofectamine 2000 (Invitrogen) was used according to manufacturer's instruction. Six hours post-transfection, MARC-145 cells were infected with Highly pathogenic PRRSV GD isolate (kindly provided by Dr. Guihong Zhang in South China Agricultural University, China) at a multiplicity of infection of 0.01 as described in previous study.
Dual luciferase reporter assays
Luciferase reporter assays were performed using the psiCHECK2-GP5 and psiCHECK2-M. 293FT cells were grown to approximately 80% confluence in 24-well plates and cotransfected with psiCHECK2-GP5, psiCHECK2-M or psiCHECK2 empty vector plus 0.2 μg, 0.5 μg or 0.8 μg pcDNA™6.2-GW/EmGFP-miR. Cells were incubated with transfection reagent lipofectamine 2000/DNA complex for 6 hours and then refreshed with fresh DMEM containing 1% FBS for 48 hours. Firefly and Renilla luciferase activities were evaluated using the Dual-Luciferase Reporter Assay system (Promega), and Renilla luciferase activity was normalized to firefly luciferase activity.
MARC-145 cells were typsinized and seeded in 96-well plate 24 hours before virus infection. Virus supernatants were 10-fold serially diluted and added 100 μl to each well in eight repeated. Six days after infection, the 50% cell culture infection dose (CCID50) was calculated by the Reed-Muench method.
Analysis of PRRSV GP5 and M protein coding genes by real-time PCR
Total RNA was isolated from MARC-145 cells at 60 h after H-PRRSV infection as described above using RNApreppure total cell RNA isolation kit (Tiangen, Beijing, China). Genomic DNA was removed using DNase I (NEB). 2 μg RNA was reverse-transcribed into first strand cDNA with M-MLV transcriptase (Promega) and oligo d(T)18 primers (TaKaRa). 1 μl cDNA was submitted to real-time PCR analysis using specific primers for β-actin, PRRSV GP5 and M protein coding genes. β-actin-F:5'TGACTGACTACCTCATGAAGATCC3';β-actin-R:5'TCTCCTTAATGTCACGCACGATT3', GP5-F:5'ACTCACCACCAGCCATTTC3';GP5-R: 5' CAGTTCTTCGCAAGCCTAA 3', M-F: 5' CACCTCCAGATGCCGTTTG 3'; M-R: 5' ATGCGTGGTTATCATTTGCC 3', and SYBR® Premix Ex Taq™ (TaKaRa). Real-time PCR was performed in a LightCycler® 480 Real-Time PCR System and analyzed with LightCycler® 480software (Roche). Amplification was carried out in a 10 μl reaction mixture containing 5 μl SYBR® Premix Ex Taq™ (TaKaRa) 2×, 0.2 μM concentration of each primer, 1 μl cDNA. The reaction procedure was 95°C 10s, followed by 40 cycles at 95°C for 5s and 60°C for 40s. β-actin gene was served as an internal reference. To confirm specific amplification, melting curve analysis was performed.
MARC-145 cells seeded in 96-well plate were transfected with pcDNA™6.2-GW/EmGFP-amiR-GP5-370, pcDNA™6.2-GW/EmGFP-amiR-M-263-M-263 or pcDNA™6.2-GW/EmGFP-amiR-negative, and then were infected with H-PRRSV. At 60 hours after virus infection, MARC-145 cells were fixed with pre-cooled methanol for 20 minutes on ice. Following three washes by phosphate-buffer saline (PBS, pH7.4), the fixed MAR-145 cells were incubated with PRRSV positive serum for 2 hours at 37°C. Unbound antibodies were washed three times with TBST. Then, FITC labeled goat anti-pig IgG antibody (KPL) was added and incubated for 1 hour at 37°C. After 3 washes by TBST, fluorescence was analyzed using a fluorescence microscopy (Nikon).
Western blotting analysis
Western blotting was processed as described previously. The PVDF membrane was probed with a 1:100 dilution of PRRSV positive serum. To normalize protein loading, the PVDF membrane was simultaneously incubated with mouse β-actin monoclonal antibody (BioVision, CA, USA) at a dilution of 1: 4,000. The horseradish peroxidase-conjugated goat anti-pig IgG at a dilution of 1:1,000 and horseradish peroxidase-conjugated goat anti-mouse IgG at a dilution of 1:5,000 was used as secondary antibodies. The protein bands were visualized using supersignal west pico chemiluminescence substrate (Pierce, IL, USA) and Image Quant RT ECL detector (GE).
RT-PCR for interferon assay
293FT cells were respectively transfected with 1 μg amiRNA construct in 24-well plate (pcDNA™6.2-GW/EmGFP-amiR-GP5-370 or pcDNA™6.2-GW/EmGFP-amiR-M-263-M-263) using Lipofectamine 2000 (Invitrogen). The 2 μg poly I:C (Sigma) that was transfected into 293FT cells in 24-well plate served as a positive control for innate response induction as described previously and native 293FT cells served as a negative control. Total RNA was isolated from 293FT cells 24 h post-treated using RNApreppure total cell RNA isolation kit (Tiangen, Beijing, China). Genomic DNA was removed using DNase I (NEB). RNA (2 μg) was reverse-transcribed into first strand cDNA with M-MLV transcriptase (Promega) and random hexamer primers (TaKaRa).
PCR amplification was performed on 1 μl RT product with interferon-β(IFN-β), 2',5'-oligoadenylate synthetase (OAS) and β-actin(endogenous control) specific primers. IFN-β-F: 5' GATTCATCTAGCACTGGCTGG 3'; IFN-β-R: 5' CTTCAGGTAATGCAGAATCC 3'(186 bp), OAS-F: 5' AGTGCATCTTGGGGGAAAG 3'; OAS-R: 5' CATTACCCTCCCATCAGGTGC 3' (302 bp) and β-actin-F: 5' GACTACCTCATGAAGATCCTCAC 3'; β-actin-R: 5' ATTGCCAATGGTGATGACCTG 3' (197 bp) .
Production of recombinant adenoviruses
The pDONR™ 211 vector was used as intermediate to transfer the pre-amiRNA expression cassette constructed before into the lentiviral expression plasmid (pLenti6/V5-DEST) using Gateway technology (Invitrogen) to generate pLenti6/V5-GW/EmGFP-miR. The pLenti6/V5-GW/EmGFP-miR then was co-transfected with packaging vectors (Invitrogen) into 293FT cells using lipofectamine 2000 (Invitrogen). The cell supernatants were collected at 72 h post-transfection and used as a virus stock. All lentiviruses expressed enhanced green fluorescence protein (GFP), allowing for titering and measuring their infection efficiency in transfected cells. The viral titers were determined by counting GFP-positive cells after transduced in the presence of polybrene (6 μg).
Statistical significance was determined by student's t-test. A P-value<0.05 was considered statistical significant. N values represent the number independent experiments.
List of abbreviations
Highly pathogenic porcine reproductive and respiratory syndrome
porcine reproductive and respiratory syndrome virus
highly pathogenic porcine reproductive and respiratory syndrome virus
small interference RNA
short hairpin RNA
50% cell culture infection dose
green fluorescence protein.
This research was supported by National Natural Science Foundation of China (Grant No. 31101690) and and National Industry Technology System of Modern Agriculture Projects (Grant No. nycytx-009) and Guangdong Industry Technology System of Modern Agriculture Projects.
- Xiao S, Jia J, Mo D, Wang Q, Qin L, He Z, Zhao X, Huang Y, Li A, Yu J, et al.: Understanding PRRSV infection in porcine lung based on genome-wide transcriptome response identified by deep sequencing. PLoS One 2010, 5: e11377. 10.1371/journal.pone.0011377PubMed CentralView ArticlePubMedGoogle Scholar
- Neumann EJ, Kliebenstein JB, Johnson CD, Mabry JW, Bush EJ, Seitzinger AH, Green AL, Zimmerman JJ: Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc 2005, 227: 385-392. 10.2460/javma.2005.227.385View ArticlePubMedGoogle Scholar
- Meulenberg JJ, Hulst MM, de Meijer EJ, Moonen PL, den Besten A, de Kluyver EP, Wensvoort G, Moormann RJ: Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV. Virology 1993, 192: 62-72. 10.1006/viro.1993.1008View ArticlePubMedGoogle Scholar
- Dea S, Gagnon CA, Mardassi H, Pirzadeh B, Rogan D: Current knowledge on the structural proteins of porcine reproductive and respiratory syndrome (PRRS) virus: comparison of the North American and European isolates. Archives of virology 2000, 145: 659-688. 10.1007/s007050050662View ArticlePubMedGoogle Scholar
- Delputte PL, Meerts P, Costers S, Nauwynck HJ: Effect of virus-specific antibodies on attachment, internalization and infection of porcine reproductive and respiratory syndrome virus in primary macrophages. Vet Immunol Immunopathol 2004, 102: 179-188. 10.1016/j.vetimm.2004.09.007View ArticlePubMedGoogle Scholar
- Snijder EJ, Dobbe JC, Spaan WJ: Heterodimerization of the two major envelope proteins is essential for arterivirus infectivity. Journal of virology 2003, 77: 97-104. 10.1128/JVI.77.1.97-104.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Fernandez A, Suarez P, Castro JM, Tabares E, Diaz-Guerra M: Characterization of regions in the GP5 protein of porcine reproductive and respiratory syndrome virus required to induce apoptotic cell death. Virus Res 2002, 83: 103-118. 10.1016/S0168-1702(01)00426-9View ArticlePubMedGoogle Scholar
- Verheije MH, Welting TJ, Jansen HT, Rottier PJ, Meulenberg JJ: Chimeric arteriviruses generated by swapping of the M protein ectodomain rule out a role of this domain in viral targeting. Virology 2002, 303: 364-373. 10.1006/viro.2002.1711View ArticlePubMedGoogle Scholar
- Delputte PL, Vanderheijden N, Nauwynck HJ, Pensaert MB: Involvement of the matrix protein in attachment of porcine reproductive and respiratory syndrome virus to a heparinlike receptor on porcine alveolar macrophages. J Virol 2002, 76: 4312-4320. 10.1128/JVI.76.9.4312-4320.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Van Breedam W, Van Gorp H, Zhang JQ, Crocker PR, Delputte PL, Nauwynck HJ: The M/GP(5) glycoprotein complex of porcine reproductive and respiratory syndrome virus binds the sialoadhesin receptor in a sialic acid-dependent manner. PLoS pathogens 2010, 6: e1000730. 10.1371/journal.ppat.1000730PubMed CentralView ArticlePubMedGoogle Scholar
- Tian K, Yu X, Zhao T, Feng Y, Cao Z, Wang C, Hu Y, Chen X, Hu D, Tian X, et al.: Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS ONE 2007, 2: e526. 10.1371/journal.pone.0000526PubMed CentralView ArticlePubMedGoogle Scholar
- Xiao S, Mo D, Wang Q, Jia J, Qin L, Yu X, Niu Y, Zhao X, Liu X, Chen Y: Aberrant host immune response induced by highly virulent PRRSV identified by digital gene expression tag profiling. BMC Genomics 2010, 11: 544. 10.1186/1471-2164-11-544PubMed CentralView ArticlePubMedGoogle Scholar
- Cogoni C, Romano N, Macino G: Suppression of gene expression by homologous transgenes. Antonie van Leeuwenhoek 1994, 65: 205-209. 10.1007/BF00871948View ArticlePubMedGoogle Scholar
- Sharp PA, Zamore PD: Molecular biology. RNA interference. Science (New York, NY) 2000, 287: 2431-2433.View ArticleGoogle Scholar
- Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proceedings of the National Academy of Sciences of the United States of America 2003, 100: 2718-2723. 10.1073/pnas.0437841100PubMed CentralView ArticlePubMedGoogle Scholar
- Kanda T, Kusov Y, Yokosuka O, Gauss-Muller V: Interference of hepatitis A virus replication by small interfering RNAs. Biochemical and biophysical research communications 2004, 318: 341-345. 10.1016/j.bbrc.2004.03.194View ArticlePubMedGoogle Scholar
- Christopher-Hennings J, Nelson EA, Hines RJ, Nelson JK, Swenson SL, Zimmerman JJ, Chase CL, Yaeger MJ, Benfield DA: Persistence of porcine reproductive and respiratory syndrome virus in serum and semen of adult boars. J Vet Diagn Invest 1995, 7: 456-464. 10.1177/104063879500700406View ArticlePubMedGoogle Scholar
- Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et al.: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (New York, NY) 2003, 9: 493-501.View ArticleGoogle Scholar
- Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature genetics 2003, 33: 401-406. 10.1038/ng1117View ArticlePubMedGoogle Scholar
- Manjunath N, Wu H: Subramanya S, Shankar P: Lentiviral delivery of short hairpin RNAs. Advanced drug delivery reviews 2009, 61: 732-745. 10.1016/j.addr.2009.03.004PubMed CentralView ArticlePubMedGoogle Scholar
- Liu YP, Haasnoot J, ter Brake O, Berkhout B, Konstantinova P: Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic acids research 2008, 36: 2811-2824. 10.1093/nar/gkn109PubMed CentralView ArticlePubMedGoogle Scholar
- Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic acids research 2004, 32: 1154-1158. 10.1093/nar/gkh278PubMed CentralView ArticlePubMedGoogle Scholar
- Qu J, Ye J, Fang R: Artificial microRNA-mediated virus resistance in plants. Journal of virology 2007, 81: 6690-6699. 10.1128/JVI.02457-06PubMed CentralView ArticlePubMedGoogle Scholar
- Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, et al.: Second-generation shRNA libraries covering the mouse and human genomes. Nature genetics 2005, 37: 1281-1288.PubMedGoogle Scholar
- Liu YP, von Eije KJ, Schopman NC, Westerink JT, ter Brake O, Haasnoot J, Berkhout B: Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther 2009, 17: 1712-1723. 10.1038/mt.2009.176PubMed CentralView ArticlePubMedGoogle Scholar
- Daly C, Reich NC: Double-stranded RNA activates novel factors that bind to the interferon-stimulated response element. Molecular and cellular biology 1993, 13: 3756-3764.PubMed CentralView ArticlePubMedGoogle Scholar
- Kenworthy R, Lambert D, Yang F, Wang N, Chen Z, Zhu H, Zhu F, Liu C, Li K, Tang H: Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic acids research 2009, 37: 6587-6599. 10.1093/nar/gkp714PubMed CentralView ArticlePubMedGoogle Scholar
- Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N: Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine 2009, 27: 3704-3718. 10.1016/j.vaccine.2009.04.022View ArticlePubMedGoogle Scholar
- Huang J, Jiang P, Li Y, Xu J, Jiang W, Wang X: Inhibition of porcine reproductive and respiratory syndrome virus replication by short hairpin RNA in MARC-145 cells. Vet Microbiol 2006, 115: 302-310. 10.1016/j.vetmic.2006.02.018View ArticlePubMedGoogle Scholar
- He YX, Hua RH, Zhou YJ, Qiu HJ, Tong GZ: Interference of porcine reproductive and respiratory syndrome virus replication on MARC-145 cells using DNA-based short interfering RNAs. Antiviral Res 2007, 74: 83-91. 10.1016/j.antiviral.2006.04.013View ArticlePubMedGoogle Scholar
- Li G, Huang J, Jiang P, Li Y, Jiang W, Wang X: Suppression of porcine reproductive and respiratory syndrome virus replication in MARC-145 cells by shRNA targeting ORF1 region. Virus Genes 2007, 35: 673-679. 10.1007/s11262-007-0134-8View ArticlePubMedGoogle Scholar
- Li G, Jiang P, Li Y, Wang X, Huang J, Du Y, Zeshan B: Effective suppression of replication of porcine reproductive and respiratory syndrome virus by adenovirus-mediated small interfering RNAs targeting ORF1b, 5 and 7 genes. J Virol Methods 2009, 157: 40-46. 10.1016/j.jviromet.2008.12.001View ArticlePubMedGoogle Scholar
- Li G, Jiang P, Li Y, Wang X, Huang J, Bai J, Cao J, Wu B, Chen N, Zeshan B: Inhibition of porcine reproductive and respiratory syndrome virus replication by adenovirus-mediated RNA interference both in porcine alveolar macrophages and swine. Antiviral research 2009, 82: 157-165. 10.1016/j.antiviral.2009.02.202View ArticlePubMedGoogle Scholar
- Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, Fei L, Liu Y, Zuo X, Yang F, et al.: Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J Virol 2006, 80: 3559-3566. 10.1128/JVI.80.7.3559-3566.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Carmona S, Ely A, Crowther C, Moolla N, Salazar FH, Marion PL, Ferry N, Weinberg MS, Arbuthnot P: Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther 2006, 13: 411-421. 10.1016/j.ymthe.2005.10.013View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5View ArticlePubMedGoogle Scholar
- Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441: 537-541. 10.1038/nature04791View ArticlePubMedGoogle Scholar
- Giering JC, Grimm D, Storm TA, Kay MA: Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008, 16: 1630-1636. 10.1038/mt.2008.144View ArticlePubMedGoogle Scholar
- Grimm D, Kay MA: Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? The Journal of clinical investigation 2007, 117: 3633-3641. 10.1172/JCI34129PubMed CentralView ArticlePubMedGoogle Scholar
- Rao DD, Senzer N, Cleary MA, Nemunaitis J: Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer gene therapy 2009, 16: 807-809. 10.1038/cgt.2009.53View ArticlePubMedGoogle Scholar
- Wiznerowicz M, Szulc J, Trono D: Tuning silence: conditional systems for RNA interference. Nature methods 2006, 3: 682-688. 10.1038/nmeth914View ArticlePubMedGoogle Scholar
- Xiao S, Wang Q, Jia J, Cong P, Mo D, Yu X, Qin L, Li A, Niu Y, Zhu K, et al.: Proteome changes of lungs artificially infected with H-PRRSV and N-PRRSV by two-dimensional fluorescence difference gel electrophoresis. Virol J 2010, 7: 107. 10.1186/1743-422X-7-107PubMed CentralView ArticlePubMedGoogle Scholar
- Liu YP, Haasnoot J, Berkhout B: Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic acids research 2007, 35: 5683-5693. 10.1093/nar/gkm596PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.